1. Factor Xa Inhibitors in PAD

3. COMPASS Trial Design

4. COMPASS Primary Efficacy Outcome—CV Death/MI/Stroke

5. COMPASS Bleeding Outcomes

6. Global Burden of PAD

7. Clinical Presentation of PAD

8. Patients at Increased Risk for PAD

9. AHA/ACC Guidelines Antiplatelet Agents

10. Aspirin for Secondary Prevention of Vascular Disease

11. CHARISMA Single vs Dual Antiplatelet Therapy for PAD

12. WAVE Oral Anticoagulation for PAD

13. EUCLID Ticagrelor vs Clopidogrel for PAD

14. COMPASS PAD Cohort Eligibility Criteria

15. COMPASS PAD Cohort CV Death, Stroke, MI

16. COMPASS PAD Cohort Peripheral Limb Outcomes

17. COMPASS Stroke Outcomes

18. COMPASS PAD Cohort Risk of Vascular Amputation After MALE

19. COMPASS PAD Cohort Prognosis 1 Year After MALE

20. COMPASS PAD Cohort Prognosis After MALE by Treatment Group

21. COMPASS PAD Cohort Bleeding Outcomes

22. Potential Candidates for Rivaroxaban Therapy

23. VOYAGER PAD

24. Summary

25. Abbreviations

26. Abbreviations (cont)